ClinicalTrials.govpublic full text
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
myelodysplastic syndrome, recurrent myelodysplastic syndrome, refractory myelodysplastic syndrome, mds, high risk mds, hr-mds, relapsed or refractory, r/r, relapsed or refractory higher-risk myelodysplastic syndrome, acute myeloid leukemia, aml, bone marrow mononuclear cells
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 865414
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.